Clinician’s Brief spotlights regenerative therapies in practice: full analysis
Version 2 — Full analysis
Clinician’s Brief has added regenerative medicine to the general practice conversation with a new sponsored podcast episode, “Incorporating Regenerative Therapies Into Practice With Dr. Malhotra.” In the 31-minute episode, host Dr. Beth Mollison speaks with Dr. Rohit Malhotra about what regenerative medicine includes, which patients may be good candidates, and what it takes for a clinic to bring these therapies into routine use. The episode is sponsored by Hilltop Bio, a company focused on veterinary regenerative biologics. (podcasts.apple.com)
The timing fits a larger trend in veterinary medicine. Regenerative therapies have been discussed for years in referral, sports medicine, and rehabilitation settings, especially for osteoarthritis, soft tissue injury, and wound management. More recently, companies and veterinary media outlets have been presenting them as tools that may be feasible in general practice, not just specialty care. Hilltop Bio has been expanding its commercial footprint, including a distribution partnership announced in November 2025 with Midwest Veterinary Supply to broaden access to its equine and companion animal products. (merckvetmanual.com)
Hilltop Bio’s own materials describe regenerative biologics as products designed to work through the body’s healing mechanisms rather than symptom control alone. The company says its products are used in more than 1,000 clinics and that it is running four targeted studies intended to generate data relevant to FDA regulatory standards. Its science page emphasizes characterization of product components, including exosomes, extracellular matrix proteins, and growth factors, and distinguishes its approach from PRP-, stem cell-, or serum-based options. Those claims help explain why a practice-focused educational discussion is timely: many veterinarians are now encountering multiple regenerative platforms with different sourcing, handling, and evidentiary profiles. (hilltopbio.com)
Dr. Malhotra appears to be part of that commercialization and education push. Hilltop Bio announced in April 2026 that he joined its new Canine Advisory Board, alongside other veterinary advisers, to provide clinical insight on companion animal strategy. That affiliation is worth noting for readers because it places the podcast in the context of sponsored professional education tied to a company actively building market access and clinical visibility. Clinician’s Brief’s advertising policy says sponsored content is supported by companies aligned with its mission and may be subject to review for appropriateness and patient safety. (hilltopbio.com)
Outside the marketing narrative, the literature still calls for caution. Merck Veterinary Manual says regenerative treatments, including mesenchymal stem cells, platelet-rich plasma, and autologous serum products, have become increasingly popular in horses and dogs, particularly for osteoarthritis and soft tissue conditions. But reviews of mesenchymal stem cell therapy in canine osteoarthritis describe the evidence as promising rather than definitive, and some authors have argued commercialization has moved ahead of a robust clinical evidence base. In other words, enthusiasm is real, but so are the unanswered questions about standardization, durability of response, comparative effectiveness, and ideal patient selection. (merckvetmanual.com)
Why it matters: For veterinary professionals, this is less a story about one podcast than about a category maturing in public. As regenerative medicine moves into general practice, clinics will need to decide whether these therapies fit their standards of care, workflows, and client communication. That includes practical questions around storage, administration, training, pricing, and documentation, but also tougher questions around evidence quality and oversight. FDA says it oversees animal cell and tissue products used in veterinary regenerative medicine, and the regulatory path can vary by product type. For clinicians, that raises the bar on due diligence before recommending a therapy to a pet parent, especially when claims outpace peer-reviewed data. (fda.gov)
Expert reaction in the classic quote-driven sense was limited in publicly available coverage of this specific episode, but the broader industry response is clear: regenerative medicine is being positioned as a growth area in companion animal care, with new advisory boards, distributor relationships, and continuing education content aimed at normalizing adoption. That suggests the next phase will be less about awareness and more about proof, namely published studies, clearer regulatory framing, and whether practices see repeatable outcomes that justify cost and workflow changes. (hilltopbio.com)
What to watch: Watch for peer-reviewed data tied to specific veterinary regenerative products, more explicit FDA-facing regulatory language from manufacturers, and whether general practices begin treating regenerative medicine as a niche add-on or a standard part of multimodal care. (hilltopbio.com)